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Identification of CANT1 Mutations
in Desbuquois Dysplasia
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Yasemin Alanay,3 Lihadh I. Al-Gazali,4 Margreet G.E.M. Ausems,5 Pierre Bitoun,6 Denise P. Cavalcanti,7
Alexander Krebs,8 Martine Le Merrer,1 Geert Mortier,9 Yousef Shafeghati,10 Andrea Superti-Furga,11
Stephen P. Robertson,12 Carine Le Goff,1 Andrea Onetti Muda,13 Patrizia Paterlini-Bre´chot,1
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Desbuquois dysplasia is a severe condition characterized by short stature, joint laxity, scoliosis, and advanced carpal ossiﬁcation with
a delta phalanx. Studying nine Desbuquois families, we identiﬁed seven distinct mutations in the Calcium-Activated Nucleotidase 1
gene (CANT1), which encodes a soluble UDP-preferring nucleotidase belonging to the apyrase family. Among the seven mutations,
four were nonsense mutations (Del 50 UTR and exon 1, p.P245RfsX3, p.S303AfsX20, and p.W125X), and three were missense mutations
(p.R300C, p.R300H, and p.P299L) responsible for the change of conserved amino acids located in the seventh nucleotidase conserved
region (NRC). The arginine substitution at position 300 was identiﬁed in ﬁve out of nine families. The speciﬁc function of CANT1 is as
yet unknown, but its substrates are involved in several major signaling functions, including Ca2þ release, through activation of
pyrimidinergic signaling. Importantly, using RT-PCR analysis, we observed a speciﬁc expression in chondrocytes. We also found elec-
tron-dense material within distended rough endoplasmic reticulum in the ﬁbroblasts of Desbuquois patients. Our ﬁndings demonstrate
the speciﬁc involvement of a nucleotidase in the endochondral ossiﬁcation process.Desbuquois dysplasia (DBQD) is an autosomal-recessive
chondrodysplasia belonging to the multiple dislocation
group1 and characterized by severe prenatal and postnatal
growth retardation (<5 SD), joint laxity, short extremi-
ties, and progressive scoliosis. The main radiological
features are short long bones with metaphyseal splay,
a ‘‘swedish key’’ appearance of the proximal femur (exag-
gerated trochanter), and advanced carpal and tarsal bone
age with a delta phalanx (Figure 1).2,3 We have previously
distinguished two forms of Desbuquois dysplasia on the
basis of the presence (type 1) or absence (type 2) of charac-
teristic hand anomalies4, and we have subsequently map-
ped the Desbuquois type 1 gene to a 1.65 Mb interval on
chromosome 17q25.5
We report here the identiﬁcation of calcium-activated
nucleotidase 1 (CANT1) mutations in nine families with
Desbuquois type 1. This gene encodes a soluble nucleo-
tidase that preferentially hydrolyzes UDP followed by
GDP and UTP but whose speciﬁc function is as yet
unknown.6,7 Interestingly, we also found a distended
rough endoplasmic reticulum (ER) in patient ﬁbroblasts
compared to controls.
Criteria for inclusion in the study were severe prenatal
and postnatal growth retardation, joint laxity, short long706 The American Journal of Human Genetics 85, 706–710, Novembones, a Swedish key appearance of the proximal femur,
and advanced carpal bone age with delta phalanx (Fig-
ure 1). A total of ten children who had Desbuquois
dysplasia type 1 and belonged to nine families were
included in the study. Eight families were consanguin-
eous and originated from Turkey, Sri Lanka, Iran, United
Arab Emirates, Morocco, or France. Table 1 summarizes
the major clinical ﬁndings for these families. Blood
samples were obtained with written consent in accor-
dance with the French ethical standards regarding human
subjects.
Using the human genome resources (Ensembl and UCSC
Browser), we selected several candidate genes among the
14 genes located in our region of interest of 1.65 Mb on
chromosome 17q25. These genes included the STAT
induced inhibitor-3 gene (SSI-3), the phosphatidylglycero-
phosphate synthase gene (PGS1), the Pleckstrin homology
Sec 7 and coiled/coil domains 1 gene (PSCD1), the human
tissue inhibitor of metalloproteinases 2 gene (TIMP2), the
C1q and tumor necrosis factor-related protein 1 gene
(C1QTNF1), and the lectin galactoside-binding soluble 3
binding protein gene (LGALS3BP). After having excluded
these six genes by direct sequencing, we considered the
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candidate. CANT1, a member of the apyrase family, is a
soluble nucleotidase that preferentially hydrolyzes UDP
followed by GDP and UTP.6,7 Its exact function in humans
remains unclear.8
CANT1 is composed of ﬁve coding exons and has three
transcripts (Figure 2). The ﬁrst transcript encodes a protein
of 401 amino acids, characterized by eight nucleotidase
conserved regions (NRC).9 By direct sequencing, we identi-
ﬁed three missense and four nonsense mutations
(including a large deletion of 2703 bp encompassing the
50 UTR and exon 1) in a total of nine Desbuquois type 1
families (Table 2). The mutations were located throughout
the gene (Figure 2). They cosegregated with the disease and
were not identiﬁed in 210 control chromosomes. The
missense mutations (p.R300H, p.R300C, and p.P299L)
were responsible for the change of conserved amino acids
located in NCR7. The substitution of arginine at position
300 was identiﬁed at the homozygote state in ﬁve out of
nine families.
To further understand the function of CANT1 in
humans, we studied its expression pattern by RT-PCR anal-
ysis and were able to observe a speciﬁc signal in control
lymphocytes, cultured skin ﬁbroblasts, and chondrocytes
but not in osteoblasts. A speciﬁc CANT1 mRNA signal
was still detected in Desbuquois dysplasia patients’ ﬁbro-
blasts and lymphocytes, which carried homozygous
p.P245RfsX3 and p.R300H mutations. Yet, CANT1 mRNA
was not detectable in patient 1, who presented a large
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Figure 1. Radiological Manifestations of Desbuquois Dysplasia
(A and B) Hand X-rays at 1 and 3 years of age. Note the advanced
carpal ossiﬁcation and the delta phalanx (arrow).
(C) Hip at 3 years of age. Note the Swedish key appearance of the
proximal femur.
(D) Knee at 3 years of age. Note the metaphyseal irregularities.The Americanhomozygous deletion encompassing the 50 UTR region
and the noncoding exon 1 (Figure 3).
The presence of inclusion bodies within distended
rough endoplasmic reticulum (RER) in Desbuquois patient
chondrocytes10 prompted us to further study the cultured
skin ﬁbroblasts of our patients. Ultrastructural analysis
of cultured ﬁbroblasts from three Desbuquois patients
demonstrated the presence of dilated RER cisternae con-
taining proteinaceous material (Figure 4), comparable to
what has been reported in chondrocytes. Importantly, dila-
tation of RER was not observed in three control cultured
ﬁbroblasts from the same age and same passage.
Here, we report seven distinct CANT1 mutations in
nine families with Desbuquois dysplasia type 1. These
mutations include four nonsense and three missense
mutations. All missense mutations are located in the
NCR7-encoding region, which is highly conserved among
related apyrases, and two of them (identiﬁed in ﬁve out of
nine families) substitute arginine at position 300.9 This
amino acid belongs to a pentad of alternating positively
and negatively charged residues (Asp 114, Lys 394,
Glu 365, Arg 300, and Glu 284) that comprise a network
of four salt bridges involved in the catalytic site of
CANT1.11 Direct mutagenesis of Arg 300 has been
shown to disrupt the electrostatic interactions in the salt
bridge and result in decreased enzyme activity without
altering calcium binding or producing a conformational
change.11
All children presented with similar skeletal manifesta-
tions. However, an early death due to cardio-respiratory
failure was observed in children with nonsense mutations.
Among the whole series, extra-skeletal manifestations
included heart defects (three out of ten), mental retarda-
tion (two), glaucoma (one), and hydronephrosis (one out
of ten).
The speciﬁc function of CANT1 in humans, as well as its
cellular localization, is unknown.
Desbuquois syndrome shares phenotypic features,
namely advanced carpal bone maturation, with Dia-
strophic dysplasia (DTD), and it also shares features,
namely congenital joint dislocations, with recessive Larsen
syndrome (CHST3 deﬁciency). Both DTD and CHST3 deﬁ-
ciency involve a defect in sulfation, the ﬁnal step of proteo-
glycan synthesis. CANT1 deﬁciency might interfere with
the availability of UDP-sugars needed for proteoglycan
synthesis. However, to date, the involvement of CANT1
in proteoglycan synthesis has not been demonstrated.12
CANT1 substrates (UDP > GDP > UTP) are involved in
several major signaling functions, notably in calcium re-
lease, through activation of pyrimidinergic signaling.8,13,14
Indeed, the binding of pyrimidinergic nucleotides (UTP/
UDP) to P2Y receptors generates inositol 1,4,5-triphos-
phate (IP3) through their coupling to phospholipase
C.8,14 IP3 binding to the IP3 receptor at the surface of the
endoplasmic reticulum (ER) allows rapid release of calcium
from the intracellular stores.13 However, the link between
CANT1 mutations and RER distension (observed inJournal of Human Genetics 85, 706–710, November 13, 2009 707
Table 1. Clinical Manifestations in the Nine Families with Desbuquois Syndrome Type 1
Family Origin Sex Age
Birth
Length
Height
(SD)
Other
Anomalies
Orthopedic
Surgery
Scoliosis/
Lordosis
Walking
difficulties
Joint
dislocation
1 Sri Lanka F Death: day 2
Heart failure
34 cm
(35 WG)
10 SD Atrial septal
defect
- - - Hip, knee,
elbow
2 Turkey M Terminated
pregnancy
34 WG
33 cm
(34 WG)
33 cm Polyhydramnios - - - Hip, knee
3 Turkey M 18 months 34 cm 12 SD Delay in verbal
speech
Yes, knees - Not ambulatory
sits without
support
Hip, knee
4 Turkey F 20 months ? 4SD - Yes, knees Thoracic
scoliosis
Yes Left elbow and
both knees
5 Iran M 4 years ? 9 SD - - Not ambulatory
without any
support
Hip and Knee
6 France M 27 years 43 cm
(term)
8SD Glaucoma Yes, knees Lordosis Yes Hip, knee and
ﬁngers
7 United Arab
Emirates
M 4 years on report
(17 years now)
? < 4SD Mental
retardation
Yes, hips
and knees
Lordosis Yes Hip and knee,
But limitation
of elbow
8 Morocco M Death: 3 months
Cardio-respiratory
failure
37 cm < 6SD - - - - Elbow, hip and
right knee
9 Brazil
Case 1
M Neonatal death 36 cm
(37 WG)
36 cm Omphalocele,
Pulmonary
hypoplasia,
Ventricular
septal defect,
Hydronephrosis
- - - Multiple
dislocation
Case 2 M Neonatal death 35 cm
(39 WG)
35 cm Pulmonary
hypoplasia,
Coarctation
of aorta
- - - Multiple
dislocation
WG: weeks of gestation. ?: unknown. -: no clinical manifestation.chondrocytes and ﬁbroblasts of Desbuquois dysplasia
patients) is unclear but may be related to impaired ER func-
tion. Accordingly, deletion of APY-1, the Caenorhabditis
elegans homolog of CANT1, sensitized worms to ER stress
and induced defects in pharynx and muscle organization,
leading to a reduced lifespan.15
With the identiﬁcation of CANT1 mutations in Desbu-
quois dysplasia, we demonstrate for the ﬁrst time, to our
knowledge, the key role of a nucleotidase in the endochon-
dral ossiﬁcation process. It is hoped that future studies will
lead to further understanding of the speciﬁc function of
CANT1 in the endochondral ossiﬁcation process.
Ex 2 Ex 3
Transcript 1
ENST00000302345
ATG
Ex 4
R300C
R300H
Ex 1
P299LW125X
TAA
Ex 4 Ex 6
ATG Ex 5Ex 1
TAA
Ex 4 Ex 6
ATG
Ex 5Ex 1
TAA
Transcript 2
ENST00000339300
Transcript 3
ENST00000392446
Above transcript 1: homozygote mutations, underneath: heterozygote mutations
Primer mRNA forward Primer mRNA reverse
Figure 2. CANT1 Mutations Identified in
Desbuquois Patients
Position of the primers used for the RT-
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Table 2. CANT1 Mutations Identified in Nine Families with Desbuquois Syndrome Type 1
Family Ethnic Origin Consanguinity
Number of
Affected Children
Nucleotide
Change
Amino
Acid Change
Location (Ref:
transcript 1)
1 Sri lanka Yes 1 del 2703 bp _ 50UTR and Ex1
2 Turkey Yes 1 c.734 delC p.P245RfsX3 Ex3
3 Turkey Yes 1 c.898C > T p.R300C Ex4
4 Turkey Yes 1 c.898C > T p.R300C Ex4
5 Iran Yes 1 c.898C > T p.R300C Ex4
6 France Yes 1 c.899G > A p.R300H Ex4
7 United Arab Emirates Yes 1 c.899G > A p.R300H Ex4
8 Morocco Yes 1 c.907-911insGCGCC p.S303AfsX20 Ex4
9 Brazil No 2 c.374G > A p.W125X Ex2
c.896C > T p.P299L Ex4Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.cell.com/AJHG/.
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Figure 3. CANT1 mRNA Expression by RT-PCR in Desbuquois
Patient Lymphocytes and Fibroblasts and in Wild-Type Chondro-
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